One additional point worth making is that Anktiva, the IL-15 superagonist at the core of BioShield, carries a non-trivial safety profile. In its approved bladder cancer indication, the FDA label reports serious adverse events in about 16 percent of patients, including one treatment-related death from cardiac arrest. Common toxicities include urinary effects such as dysuria, hematuria, urgency, and infections, along with systemic flu-like symptoms including fever and chills. In earlier systemic or higher-dose studies, inflammatory reactions consistent with cytokine release were seen, including elevated IL-6, fevers, and chills. While the intravesical dosing used in the approved setting reduces the risk of the most severe systemic effects, the fact remains that this approach depends on broad immune activation that can carry significant inflammatory risk, a stark contrast to DCVax, where dendritic cell–driven immune training delivers targeted, coordinated activation without the same systemic overdrive.
This is also why BioShield does not align with the vision Dr. Makary outlined when he spoke of potentially promising treatments for stage four metastatic disease that can achieve a complete pathologic response without chemo, surgery, or radiation. Makary has consistently emphasized evidence-based therapies supported by real-world proof. BioShield’s most striking results are anecdotal, its mechanism lacks the antigen-specific targeting needed to reliably clear “hidden” cancer cells, and its inflammatory risk profile would be a concern in the very advanced-stage patients he is talking about. By contrast, DCVax has phase III data, real-world validation, and a safety record that allows it to be deployed in fragile patients while still integrating NK cells, T cells, and the rest of the immune system into a unified, precision-guided response.
The difference becomes even clearer when looking at DCVax-Direct. In the Phase I trial for inoperable solid tumors, conducted without any booster agents such as Poly-ICLC, ll nine patients who completed at least four of the six planned injections showed evidence of tumor cell death, shrinkage, or immune infiltration, and in three of those patients, post-treatment biopsies revealed no live tumor cells at all. These were advanced, inoperable cases including metastatic pancreatic cancer, colon cancer, and sarcoma. Across the broader cohort, 13 of 20 patients who had received at least three injections exhibited similar tumor impact. Achieving complete responses in such late-stage disease without surgery, radiation, or chemotherapy, and with a clean safety record, satisfies every element of Makary’s criteria. The JAMA Oncology phase III glioblastoma trial for DCVax-L validated the dendritic cell method itself, proving that this approach can extend survival and generate long-term survivors. Together, DCVax-Direct and DCVax-L show that the method is reproducible, evidence-backed, and capable of delivering the kind of outcomes Makary described, not as anecdotes, but as documented trial results.
Market Data 
Markets 
